Dosage and administration of Idecabtagene vicleucel

Idecabtagene vicleucel is a new type of immunotherapy for relapsed or refractory multiple myeloma (MM) that utilizes autologous genetically modified T cells guided by B cell maturation antigen (BCMA). This therapy is designed for adult patients who have received two or more prior therapies, such as immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies.

Before using Elkavilenza, patients first need to undergo leukapheresis to extract their ownT cells from the blood. These T cells will then be genetically modified in a specialized laboratory to prepare Akivelense, a process that takes about four weeks. Of note, the drug is only available to patients whose cells are used to make the drug.

Prior to infusion of Elkavilenza, patients receive a short course of chemotherapy to clear existing white blood cells. In terms of specific operations, patients will receive chemotherapy within three days before the infusion, with the purpose of creating good conditions for subsequent treatment. Patients also need to take paracetamol and antihistamines 30 to 60 minutes before the infusion to reduce the risk of possible infusion reactions.

The actual infusion of Alkavilenza occurs two days after completion of lymphodepleting chemotherapy and is given intravenously through a catheter placed in a vein. Following infusion, patients must remain at the treatment center for at least 7 days and 2 hours at a time in the facility for 4 weeks for safety monitoring. This monitoring is to observe possible side effects and take timely measures.

If the patient experiences an unresolved serious adverse event (especially a pulmonary or cardiac event, hypotension, etc.) prior to infusion, or has an active infection or inflammatory disease, the infusion may be delayed for 7 days. Such precautions are intended to ensure patient safety and increase the success rate of therapy.

Reference materials:https://pubmed.ncbi.nlm.nih.gov/34854741/